Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease
Sponsor: University of Washington
Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Purpose
The primary purpose of this study is to test whether coQ10 and NR can improve muscle function among people with chronic kidney disease.
Study Design
Randomized, placebo-controlled, cross-over
Dose
CoQ10: 2x250mg tablet 2x/day (1000mg/day)
NR: 1x600mg tablet 2x/day (1200mg/day)
Length of Intervention
6 weeks, 7 day washout between treatments
Intrinsic Capacity
Locomotion
Status
Recruiting
Condition or Disease
Chronic Kidney Disease
Sarcopenia
Frailty
Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.